Uterotonic drugs in obstetric bleeding prevention and treatment

封面


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅存取

详细

One of the main causes of maternal mortality is obstetric bleeding, among which 2/3 of cases are bleeding in the early postpartum period. The existing methods of preventing and stopping uterine bleeding in the postpartum period do not always allow achieving the desired result due to the ineffectiveness of the measures taken. The aim of this study was to assess the effectiveness of existing uterotonic drugs in the obstetric bleeding prevention and treatment. We performed a detailed systematic analysis of modern domestic and foreign literature on uterotonic drugs being used to prevent and stop obstetric bleeding, with their main parameters considered. The study used such information databases as eLIBRARY.RU, Scopus, PubMed, MEDLINE, ScienceDirect, and Cochrane Library from inception to December 2020. Despite a significant number of studies devoted to exploring the possibilities of uterotonic drugs, currently there are no methods with absolute therapeutic efficacy, which requires research to develop new drugs based on their synthetic analogues.

作者简介

Aydar Ziganshin

Bashkir State Medical University

Email: zigaidar@yandex.ru
ORCID iD: 0000-0001-5474-1080

MD, PhD, Assistant Professor

俄罗斯联邦, Ufa

Ilnara Bektasheva

Bashkir State Medical University

Email: ibektasheva@gmail.com
ORCID iD: 0000-0001-9770-5039
俄罗斯联邦, Ufa

Viktor Mudrov

Chita State Medical Academy

编辑信件的主要联系方式.
Email: mudrov_viktor@mail.ru
ORCID iD: 0000-0002-5961-5400

PhDs in Medicine, assistant of professor of the obstetrics and gynecology department of the medical and dental faculties 

俄罗斯联邦, Chita

参考

  1. Maswime S, Buchmann E. A systematic review of maternal near miss and mortality due to postpartum hemorrhage. Int J Gynaecol Obstet. 2017;137(1):1–7. doi: 10.1002/ijgo.12096
  2. Baev OR, Davydov AI. Poslerodovoe krovotechenie: akusherskaya taktika i intensivnaya terapiya. Voprosy ginekologii, akusherstva i perinatologii. 2011;10(6):65–69. (In Russ.)
  3. Ziganshin AM, Mudrov VA, Lyapunov AK. Determination of the volume of early hypotonic hemorrhage by 3d modeling of ultrasound investigation results. Biomedical Engineering. 2020;54(3):169–173. doi: 10.1007/s10527-020-09997-z
  4. Nyfløt LT, Sandven I, Stray-Pedersen B, et al. Risk factors for severe postpartum hemorrhage: A case-control study. BMC Pregnancy Childbirth. 2017;17(1):17. doi: 10.1186/s12884-016-1217-0
  5. WHO recommendations: uterotonics for the prevention of postpartum haemorrhage. Geneva: World Health Organization; 2018 [¬cited 19 Jan 2021]. Available from: https://apps.who.int/iris/bitstream/handle/10665/277276/9789241550420-eng.pdf?ua=1
  6. Yarmolinskaya MI, Khobets VV. The role of oxytocin in the pathogenesis of endometriosis: various aspects of the problem. Journal of obstetrics and women’s diseases. 2019;68(3):89-98. (In Russ.). doi: 10.17816/JOWD68389-98
  7. Tsirkin VI, Trukhina SI, Trukhin AN, Anisimov KYu. Oxytocin receptors (literature review). Pt. 1. Vestnik Ural’skoi Medi-tsinskoi Akademicheskoi Nauki. 2018;15(3):470–475. (In Russ.). doi: 10.22138/2500-0918-2018-15-3-470-487
  8. Kimura T, Takemura M, Nomura S, et al. Expression of oxytocin receptor in human pregnant myometrium. Endocrinology. 1996;137(2):780–785. doi: 10.1210/endo.137.2.8593830
  9. Fuchs AR, Fuchs F, Husslein P, et al. Oxytocin receptors in the human uterus during pregnancy and parturition. Am J Obstet Gynecol. 1984;150(6):734–741. doi: 10.1016/0002-9378(84)90677-x
  10. Yulia A, Johnson MR. Myometrial oxytocin receptor expression and intracellular pathways. Minerva Ginecol. 2014;66(3):267–280.
  11. Robinson C, Schumann R, Zhang P, Young RC. Oxytocin-induced desensitization of the oxytocin receptor. Am J Obstet Gynecol. 2003;188(2):497–502. doi: 10.1067/mob.2003.22
  12. Tsirkin VI, Trukhina SI, Trukhin AN, Anisimov KYu. Oxytocin receptors (literature review). Pt. 2. Vestnik Ural’skoi Medi-tsinskoi Akademicheskoi Nauki. 2018;15(3):625–640. (In Russ.). doi: 10.22138/2500-0918-2018-15-4-625-640
  13. Heesen M, Carvalho B, Carvalho JCA, et al. International consensus statement on the use of uterotonic agents during caesarean section. Anaesthesia. 2019;74(10):1305–1319. doi: 10.1111/anae.14757
  14. Seng J. Posttraumatic oxytocin dysregulation: Is it a link among posttraumatic self disorders, posttraumatic stress disorder, and pelvic visceral dysregulation conditions in women? J Trauma Dissociation. 2010;11(4):387–406. doi: 10.1080/15299732.2010.496075
  15. Alotaibi MF. Effects of intermittent and continuous oxytocin exposure on myometrial contractile activity in term-pregnant rats in vitro. Reprod Sci. 2020;27(4):1024–1029. doi: 10.1007/s43032-019-00104-6
  16. Talati C, Carvalho JCA, Luca A, Balki M. The effect of intermittent oxytocin pretreatment on oxytocin-induced contractility of human myometrium in vitro. Anesth Analg. 2019;128(4):671–678. doi: 10.1213/ANE.0000000000002834
  17. Balki M, Ramachandran N, Lee S, Talati C. The recovery time of myometrial responsiveness after oxytocin-induced desensitization in human myometrium in vitro. Anesth Analg. 2016;122(5):1508–1515. doi: 10.1213/ANE.0000000000001268
  18. Wu Y, Wang H, Wu QY, et al. A meta-analysis of the effects of intramuscular and intravenous injection of oxytocin on the third stage of labor. Arch Gynecol Obstet. 2020;301(3):643–653. doi: 10.1007/s00404-020-05467-9
  19. Adnan N, Conlan-Trant R, McCormick C, et al. Intramuscular versus intravenous oxytocin to prevent postpartum haemorrhage at vaginal delivery: randomised controlled trial. BMJ. 2018;362:k3546. doi: 10.1136/bmj.k3546
  20. Degtyarev EN, Shifman EM, Tikhova GP, et al. Oxytocin as a risk factor for developing myocardial ischemia. Gyneco-logy, Obstetrics and Perinato¬logy. 2018;17(4):5–10. (In Russ.). doi: 10.20953/1726-1678-2018-4-5-10
  21. Rabow S, Olofsson P. Pulse wave analysis by digital photoplethysmography to record maternal hemodynamic effects of spinal anesthesia, delivery of the baby, and intravenous oxytocin during cesarean section. J Matern Fetal Neonatal Med. 2017;30(7):759–766. doi: 10.1080/14767058.2016.1186162
  22. Pantoja T, Abalos E, Chapman E, et al. Oxytocin for preventing postpartum haemorrhage (PPH) in non-facility birth settings. Cochrane Database Syst Rev. 2016;4:CD011491. doi: 10.1002/14651858.CD011491.pub2
  23. Rabow S, Hjorth U, Schönbeck S, Olofsson P. Effects of oxytocin and anaesthesia on vascular tone in pregnant women: A randomised double-blind placebo-controlled study using non-invasive pulse wave analysis. BMC Pregnancy Childbirth. 2018;18(1):453. doi: 10.1186/s12884-018-2029-1
  24. Kovacheva VP, Soens MA, Tsen LC. A randomized, double-blinded trial of a “Rule of Threes” algorithm versus continuous infusion of oxytocin during elective cesarean delivery. Anesthesiology. 2015;123(1):92–100. doi: 10.1097/ALN.0000000000000682
  25. Voskresenskiy SL. Shilkina EV, Zelenko EN, Fedoseeva NA. Giperstimuljacija matochnoj aktivnosti – faktor riska gipoksii ploda i novorozhdennogo. Reproduktivnoe zdorov’e. Vostochnaya Evropa. 2012;2(5):255–258. (In Russ.)
  26. Shifman EM, Kulikov AV, Krugova LV, et al. Safety of uterotonics: what anaesthesiologist should know about them? Anaesthesiology and Reanimatology. 2017;62(3):220–224. (In Russ.). doi: 10.18821/0201-7563-2017-62-3-220-224
  27. Cardaillac C, Rua C, Simon EG, El-Hage W. L’ocytocine et la dépression du post-partum [Oxytocin and postpartum depression]. J Gynecol Obstet Biol Reprod (Paris). 2016;45(8):786–795. doi: 10.1016/j.jgyn.2016.05.002
  28. De Winter S, Vanbrabant P, Vi NT, et al. Impact of temperature exposure on stability of drugs in a real-world out-of-hospital setting. Ann Emerg Med. 2013;62(4):380–387. doi: 10.1016/j.annemergmed.2013.04.018
  29. World Health Organization. Oxytocin: adopted text for the international pharmacopoeia: final text for addition to the international pharmacopoeia (June 2010). 4th ed. Geneva: World Health Organization; 2010 [cited 19 Jan 2021]. Available from: https://docplayer.net/23855577-Oxytocin-adopted-text-for-the-international-pharmacopoeia-final-text-for-addition-to-the-international-pharmacopoeia-june-2010.html
  30. Torloni MR, Gomes Freitas C, Kartoglu UH, et al. Quality of oxytocin available in low- and middle-income countries: a systematic review of the literature. BJOG. 2016;123(13):2076–2086. doi: 10.1111/1471-0528.13998
  31. Zhu C, Estrada M, White J, Lal M. Heat-stable sublingual oxytocin tablets as a potential needle-free approach for preventing postpartum hemorrhage in low-resource settings. Drug Deliv Transl Res. 2018;8(3):853–856. doi: 10.1007/s13346-017-0471-7
  32. Hagen N, Bizimana T, Kayumba PC, et al. Stability of oxytocin preparations in Malawi and Rwanda: stabilizing effect of chlorobutanol. Am J Trop Med Hyg. 2020;103(5):2129–2141. doi: 10.4269/ajtmh.20-0255
  33. World Health Organisation. Quality of misoprostol products. WHO Drug Inf. 2016;30(1):35-39 [cited 19 Jan 2021]. Available from: https://www.who.int/medicines/publications/druginformation/WHO_DI_30-1_Quality.pdf?ua=1
  34. Malm M, Madsen I, Kjellström J. Development and stability of a heat-stable formulation of carbetocin for the prevention of postpartum haemorrhage for use in low and middle-income countries. J Pept Sci. 2018;24(6):e3082. doi: 10.1002/psc.3082
  35. Muggleton E. Oxytocin study raises concerns about carbetocin use. Anesthesia and Analgesia. 2018;126(4):1423. doi: 10.1213/ANE.0000000000002710
  36. Cole NM, Carvalho JC, Erik-Soussi M, et al. In vitro comparative effect of carbetocin and oxytocin in pregnant human myometrium with and without oxytocin pretreatment. Anesthesiology. 2016;124(2):378–386. doi: 10.1097/ALN.0000000000000940
  37. Voon HY, Suharjono HN, Shafie AA, Bujang MA. Carbetocin versus oxytocin for the prevention of postpartum hemorrhage: A meta-ana¬lysis of randomized controlled trials in cesarean deliveries. Taiwan J Obstet Gynecol. 2018;57(3):332–339. doi: 10.1016/j.tjog.2018.04.002
  38. Amornpetchakul P, Lertbunnaphong T, Boriboonhiransarn D, et al. Intravenous carbetocin versus intravenous oxytocin for preventing atonic postpartum hemorrhage after normal vaginal delivery in high-risk singleton pregnancies: a triple-blind randomized controlled trial. Arch Gynecol Obstet. 2018;298(2):319–327. doi: 10.1007/s00404-018-4806-5
  39. Ronenson AM, Shifman EM, Kulikov AV. Pregrady na puti rutinnogo primeneniya karbetotsina. Vestnik akusherskoy anesteziologii. 2020;6(32):14–15 [cited 2021 Jan 19]. Available from: https://www.arfpoint.ru/wp-content/uploads/2020/07/32_06_2020.pdf. (In Russ.). doi: 10.24411/2686-8032-2020-00017
  40. Widmer M, Piaggio G, Nguyen TMH, et al.; WHO CHAMPION Trial Group. Heat-stable carbetocin versus oxytocin to prevent hemorrhage after vaginal birth. N Engl J Med. 2018;379(8):743–752. doi: 10.1056/NEJMoa1805489
  41. Babloyan AG, Tsakhilova SG, Sakvarelidze NYu, et al. Profilaktika akusherskikh krovotecheniy u patsientok grupp vysokogo riska. Sovremennaya lechebnaya taktika. Problemy reproduktsii. 2019;25(5):100–109. (In Russ.). doi: 1017116/repro201925051
  42. James AH, Cooper DL, Paidas MJ. Hemostatic assessment, treatment strategies, and hematology consultation in massive postpartum hemorrhage: results of a quantitative survey of obstetrician-gynecologists. Int J Womens Health. 2015;7:873–881. doi: 10.2147/IJWH.S89573
  43. Klinicheskie rekomendatsii (protokol lecheniya) № 15-4/10/2-2535 “Profilaktika, algoritm vedeniya, anesteziya i intensivnaya terapiya pri poslerodovykh krovotecheniyakh”, utverzhdennye Ministerstvom zdravookhraneniya Rossiyskoy Federatsii 26 March 2019 [cited 2021 Jan 19]. Available from: https://www.garant.ru/products/ipo/prime/doc/72186142/. (In Russ.)
  44. Gallos ID, Coomarasamy A. Carbetocin: Worth the extra expense? Best Pract Res Clin Obstet Gynaecol. 2019;61:55–65. doi: 10.1016/j.bpobgyn.2019.04.001
  45. Abediasl Z, Sheikh M, Pooransari P, et al. Vaginal misoprostol versus intravenous oxytocin for the management of second-trimester pregnancies with intrauterine fetal death: A randomized clinical trial. J Obstet Gynaecol Res. 2016;42(3):246–251. doi: 10.1111/jog.12910
  46. Momot AP, Molchanova IV, Tskhai BV. Pharmacotherapy for massive obstetric hemorrhage Obstetrics and Gynecology. 2010;4:3–10. (In Russ.)
  47. Liabsuetrakul T, Choobun T, Peeyananjarassri K, et al. Prophylactic use of ergot alkaloids in the third stage of labour. Cochrane Database Syst Rev. 2018;6(6):CD005456. doi: 10.1002/14651858.CD005456.pub3
  48. Birch S, Lu C. Ergometrine-induced atrial fibrillation at caesarean section. BMJ Case Rep. 2019;12(2):e226747. doi: 10.1136/bcr-2018-226747
  49. Pis’menskiy SV, Pyregov AV, Golubeva OA. Myocardial infraction ater cesarean section under spinal anesthesia during treatment with oxytocin and metilergometrin (clinical observation). Tol’yattinskiy meditsinskiy konsilium. 2016;(5-6):59–62. (In Russ.)
  50. Danchin N, Selton-Suty C, Juilliere Y, et al. Methylergometrine-induced coronary artery spasm causing total occlusion of all three coronary arteries. Eur Heart J. 1990;11(12):1127–1129. doi: 10.1093/oxfordjournals.eurheartj.a059655
  51. Bilgin Z, Kömürcü N. Comparison of the effects and side effects of misoprostol and oxytocin in the postpartum period: A systematic review. Taiwan J Obstet Gynecol. 2019;58(6):748–756. doi: 10.1016/j.tjog.2019.09.004
  52. Aziz S, Kazi S, Haq G, Soomro N. Oral misoprostol versus oxytocin in the management of third stage of labour. J Pak Med Assoc. 2014;64(4):428–432
  53. Radzinsky VE, Kostin IN, Savenkova IV. Misoprostol — prevention and treatment of postpartum hemorrhage (based on FIGO–2018 Congress). Obstetrics and Gynecology: News, Opinions, Training. 2018;6:30–33. (In Russ.). doi: 10.24411/2303-9698-2018-13904
  54. Yaju Y, Kataoka Y, Eto H, et al. Prophylactic interventions after delivery of placenta for reducing bleeding during the postnatal period. Cochrane Database Syst Rev. 2013;(11):CD009328. doi: 10.1002/14651858.CD009328.pub2
  55. Tan J, Cao Q, He GL, et al. Misoprostol versus ergometrine-oxytocin for preventing postpartum haemorrhage: a systematic review and meta-analysis of randomized controlled trials. J Evid Based Med. 2016;9(4):194–204. doi: 10.1111/jebm.12201
  56. Mavrides E, Allard S, Chandraharan E, et al. On behalf of the Royal College of Obstetricians and Gynaecologists. Prevention and management of postpartum haemorrhage. BJOG. 2016;124(5):e106–e149. doi: 10.1111/1471-0528.14178
  57. Sinchikhin SP, Sarbasova AE, Mamiev OB, Stepanyan LV. Prevention of increased blood loss during caesarean section: current aspects. Obstetrics and Gynecology. 2018;(4):16–20. (In Russ.). doi: 10.18565/aig.2018.4.16-20

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Ziganshin A., Bektasheva I., Mudrov V., 2021



##common.cookie##